SLC5A2 and heart failure: The timing and practical integration of these drugs in clinical practice is being refined as experience with their use expands SGLT2 inhibitors, including sotagliflozin, have been recommended as foundational therapy for patients with heart failure and reduced ejection fraction because of their favorable effects on mortality, clinical events, and quality of life.